Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the role of FVIII therapy in managing bleeding in patients with hemophilia A
- Evaluate clinical trial data for new and emerging recombinant FVIII products for the prophylactic treatment of patients with hemophilia A
- Discuss the role of pharmacokinetic-tailored prophylaxis in selecting a recombinant FVIII product for the management of hemophilia A
- Develop personalized prophylactic treatment plans for patients with hemophilia A